Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

"Further, carfilzomib has been generally well tolerated, and the compound's selectivity appears to avoid the off-target effects, such as peripheral neuropathy, associated with currently available proteasome inhibitors."

Adverse events were generally mild and manageable and carfilzomib has been well tolerated for up to one year. Of 31 patients treated, 29 percent have received 12 full cycles of treatment.

These data were reported by Dr. Stewart in an oral presentation, titled "# 0474: Safety and Efficacy Update of PX-171-004, an Open-label Phase II Trial of Carfilzomib in Relapsed Multiple Myeloma," on Saturday, June 6, 2009.

Carfilzomib Combination with Lenalidomide is Well-Tolerated; Achieves Responses in Heavily Pre-treated Patients at Low Doses

Positive preliminary data from an ongoing Phase 1b dose-escalating trial of carfilzomib in combination with lenalidomide and low-dose dexamethasone in relapsed and refractory patients was presented by Michael Wang, M.D., of the University of Texas MD Anderson Cancer Center on Sunday, June 7, 2009. The Phase 1b clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone administered on a 28-day treatment cycle. Lenalidomide in combination with dexamethasone is currently indicated for use in patients with multiple myeloma who have had at least one prior therapy.

To date, the combination of carfilzomib and lenalidomide was well tolerated in heavily pre-treated patients and adverse events were manageable. The most common adverse events reported include anemia and fatigue. No cases of peripheral neuropathy, a common adverse event associated with approved proteasome inhibitors, have been reported. A maximum-tolerated dose has not yet been established and dose-escalation in this trial continues.

Sixty-one percent of the
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Adding to their already extensive ... special – Buy 2 of any Weighing Boats ... benefit lab technicians looking for durable and reliable weighing ... for multiple applications including weighing liquids, solid, or granulated ... including diamond-shaped, hexagonal, square, aluminum weighing, and standard boats. ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 30, 2014 ... in Private Equity and Venture Capital Funding” report ... factors shaping the private equity and venture capital ... that these are expected to have significant impact ... the US and globally. Furthermore, the report identifies ...
(Date:7/29/2014)... Human Longevity, Inc. (HLI), a genomics and ... the healthy, high performance human life span, today announced ... expert in machine learning and machine translation as the ... Google where he was Distinguished Research Scientist and the ... HLI Co-Founder and CEO, J. Craig Venter , ...
(Date:7/29/2014)... Md. , July 29, 2014  The ... a new and updated program for the 9 ... – 12, 2014 in Amelia Island , ... sites and investigators remains unchanged, however, the topics ... exchange and networking opportunity among all stakeholders with ...
Breaking Biology Technology:Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3
... , , BASKING RIDGE, N.J., Sept. 4 ... of antithrombotic aptamers with active control agents, announced today that ... Officer, will be presenting at the Thomas Weisel Partners ... Friday, September 11, 2009 (EDT). Ms. McDonald,s presentation ...
... 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,the Ministry of Industry and Information Technology ... order to Sinovac to purchase H1N1 vaccine for,the national ... to complete the production of 3.3 million doses of ...
... Sept. 4 Palatin Technologies, Inc. (NYSE Amex: PTN ) ... Tuesday, September 8, 2009, before the open of the U.S. financial markets. ... and live audio webcast hosted by its executive management team on September ... greater detail and an update on corporate developments. , , ...
Cached Biology Technology:Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009 2
(Date:7/29/2014)... In this fascinating journey to the edge of science, ... new book The Beginning and the End: Does our ... it cyclic? Are we alone in the universe? What ... cosmic evolution? Grounded in science and committed to philosophical ... rise of intelligent life is not an accident, but ...
(Date:7/29/2014)... territory of Ascension Island, one of the world,s largest ... , Writing in the journal Biodiversity and Conservation ... Island Government Conservation Department report that the number of ... has increased by more than 500 per cent since ... nests are now estimated to be laid on the ...
(Date:7/29/2014)... YORK , July 29, 2014  When it comes to ... new devices, if not the last. However, when it comes to ... Though the market for the Internet of Things and its ... make an impact in the healthcare industry, whether it,s in the ... to keep us fit. With that in mind, InformationWeek ...
Breaking Biology News(10 mins):Book: 'The Beginning and the End' 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... graduate students have won $10,000 from the Dow ... solutions to some of the world,s most urgent ... one of a select number of universities that ... Dow Chemical Co. in 2009. The other schools ...
... but with major injuries, it needs help. That,s when implants ... on titanium, degradable implants are intended to replace the missing ... That may last months or even years, depending on the ... the patient. A new implant improves the conditions for the ...
... the atmosphere rise, policy makers and scientists are looking ... the greenhouse gas. One method under ... known as carbon sequestration. CCS, a newly developing technology, ... the Earth,s atmosphere. Donald J. DePaolo, ...
Cached Biology News:Tufts graduate students win $10,000 prizes 2Bone replacement from laser melting 2
... The Biomek FX provides ... analysis applications. With 96-, ... pipetting heads in either single ... Biomek FX offers maximum speed ...
... Use in any standard fixed-angle microcentrifuge ... g.,Spin- centrifuge tube filters consist ... a centrifuge tube. They filter by ... HPLC sample preparation, removal of cells ...
... The GenomeLab GeXP Genetic Analysis System ... scalable, multiplexed PCR*. The systems patented ... standard multiplexed PCR analysis to just a ... GeXP delivers more genes per reaction and ...
... The Chemicon Detergent-OUT Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... The Med column is suitable for ...
Biology Products: